Oncolytics Biotech Inc
oncolyticsbiotech.comWhat Do They Do?
Develops pelareorep, an immunotherapy being tested for gastrointestinal and other cancers, for use alongside cancer treatments.
10-K for FY2025, filed Mar 30, 2026
Who Are Their Customers?
Adlai Nortye holds exclusive rights to develop and commercialize pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan.
10-K for FY2025, filed Mar 30, 2026We entered into a Licensing Agreement with Adlai Nortye Biopharma Co., Ltd. (“Adlai”). Under the terms of the Licensing Agreement, Adlai…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$9.4MView ↗
- ▲ +79% (Loss)
- vs −$5.3M in Q2 FY2025
-
Jul 24, 2026
Nasdaq notified the company of a minimum-bid-price deficiency
It has until January 19, 2027 to regain compliance; otherwise its stock may be delisted.
Sources
8-K, filed Jul 24, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days from the date of…View ↗
-
Jul 8, 2026
The company moved to replace EY with Baker Tilly as auditor
The change followed corporate restructuring and was subject to Baker Tilly completing its client acceptance procedures.
Sources
8-K, filed Jul 8, 2026
On July 6, 2026, due to the Company’s corporate restructuring, the Audit Committee of the Board of Directors of Oncolytics Biotech Inc.…View ↗
Focus on gastrointestinal cancers
The older report emphasized metastatic breast cancer alongside pancreatic cancer, while the latest makes gastrointestinal cancers the primary focus, including colorectal, anal and pancreatic programs.
20-F for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Mar 30, 2026Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic…View ↗
Loading...
